Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 75, No 2 (2024)
Original paper
Submitted: 2023-11-11
Accepted: 2024-01-25
Published online: 2024-04-12
View PDF Download PDF file
Get Citation

Serum testosterone levels and oxidative stress in type 1 diabetes, type 2 diabetes, and obesity

Hamit Yasar Ellidag1, Rahime Aslankoç2, Mehmet Kök3, Güzin Aykal1, Özgür Aydın1, Özlem Özmen4, Remzi Can Çakır5, Uğur Doğan5
DOI: 10.5603/ep.98190
·
Pubmed: 38646988
·
Endokrynol Pol 2024;75(2):183-191.
Affiliations
  1. Department of Clinical Biochemistry, Antalya Education and Research Hospital of Ministry of Health, Antalya, Türkiye
  2. Department of Physiology, Faculty of Medicine, Suleyman Demirel University, Isparta, Türkiye
  3. Department of Internal Medicine, Antalya Education and Research Hospital of Ministry of Health, Antalya, Türkiye
  4. Department of Pathology, Faculty of Veterinary Medicine, Mehmet Akif Ersoy University, Burdur, Türkiye
  5. Department of General Surgery Antalya Education and Research Hospital of Ministry of Health, Antalya, Türkiye

open access

Vol 75, No 2 (2024)
Original Paper
Submitted: 2023-11-11
Accepted: 2024-01-25
Published online: 2024-04-12

Abstract

Introduction: Obesity, type 1 diabetes mellitus (T1DM), and type 2 diabetes mellitus (T2DM) are metabolic diseases that continue to be a global problem. Testosterone levels in men are affected by several factors, including obesity and DM. Although the relationship between diabetes and testosterone is not fully understood, oxidative stress is thought to play a major role. The aim of this study was to compare serum testosterone levels and oxidative stress markers [total antioxidant status (TAS), total oxidant capacity (TOS), oxidative stress index (OSI), and ischaemic modified albumin (IMA)] among the control group and experimentally induced obese, T1DM, and T2DM rats.

Material and methods: The study included 28 male Sprague-Dawley rats divided into 4 groups: the obesity group were fed a high-fat diet (HFD), the T2DM group received a HFD plus a single dose of streptozocin (STZ), the T1DM group received only STZ, and there was a control group. Serum testosterone, TAS, TOS, OSI, and IMA were analysed.

Results: Serum testosterone levels were lower in the T1DM and T2DM groups compared to the control and obesity groups. The TOS levels were highest in the T2DM group, followed by the T1DM group, the obesity group, and finally the control group. No significant difference was found between the obesity group and the control group in terms of TOS levels. Regarding TAS levels, the order observed was control group > obesity group > T2DM > T1DM. Testosterone was positively correlated with TAS and negatively correlated with TOS and OSI.

Conclusions: Increased oxidative stress in diabetes may be an important factor that decreases serum testosterone levels.

Abstract

Introduction: Obesity, type 1 diabetes mellitus (T1DM), and type 2 diabetes mellitus (T2DM) are metabolic diseases that continue to be a global problem. Testosterone levels in men are affected by several factors, including obesity and DM. Although the relationship between diabetes and testosterone is not fully understood, oxidative stress is thought to play a major role. The aim of this study was to compare serum testosterone levels and oxidative stress markers [total antioxidant status (TAS), total oxidant capacity (TOS), oxidative stress index (OSI), and ischaemic modified albumin (IMA)] among the control group and experimentally induced obese, T1DM, and T2DM rats.

Material and methods: The study included 28 male Sprague-Dawley rats divided into 4 groups: the obesity group were fed a high-fat diet (HFD), the T2DM group received a HFD plus a single dose of streptozocin (STZ), the T1DM group received only STZ, and there was a control group. Serum testosterone, TAS, TOS, OSI, and IMA were analysed.

Results: Serum testosterone levels were lower in the T1DM and T2DM groups compared to the control and obesity groups. The TOS levels were highest in the T2DM group, followed by the T1DM group, the obesity group, and finally the control group. No significant difference was found between the obesity group and the control group in terms of TOS levels. Regarding TAS levels, the order observed was control group > obesity group > T2DM > T1DM. Testosterone was positively correlated with TAS and negatively correlated with TOS and OSI.

Conclusions: Increased oxidative stress in diabetes may be an important factor that decreases serum testosterone levels.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

obesity; type 1 diabetes mellitus; type 2 diabetes mellitus; free radicals; oxidative stress; testosterone

About this article
Title

Serum testosterone levels and oxidative stress in type 1 diabetes, type 2 diabetes, and obesity

Journal

Endokrynologia Polska

Issue

Vol 75, No 2 (2024)

Article type

Original paper

Pages

183-191

Published online

2024-04-12

Page views

144

Article views/downloads

41

DOI

10.5603/ep.98190

Pubmed

38646988

Bibliographic record

Endokrynol Pol 2024;75(2):183-191.

Keywords

obesity
type 1 diabetes mellitus
type 2 diabetes mellitus
free radicals
oxidative stress
testosterone

Authors

Hamit Yasar Ellidag
Rahime Aslankoç
Mehmet Kök
Güzin Aykal
Özgür Aydın
Özlem Özmen
Remzi Can Çakır
Uğur Doğan

References (59)
  1. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S17–S38.
    CrossRefPubMed
  2. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384(9945): 766–781.
    CrossRefPubMed
  3. Afshin A, Forouzanfar MH, Reitsma MB, et al. GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1): 13–27.
    CrossRefPubMed
  4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016; 387(10027): 1513–1530.
    CrossRefPubMed
  5. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014; 371(12): 1131–1141.
    CrossRefPubMed
  6. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015; 1: 15019.
    CrossRefPubMed
  7. Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia. 2002; 45(9): 1201–1210.
    CrossRefPubMed
  8. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am. 2008; 37(3): 635–46, viii.
    CrossRefPubMed
  9. Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 2016; 280(5): 465–475.
    CrossRefPubMed
  10. Deutsch AJ, Ahlqvist E, Udler MS. Phenotypic and genetic classification of diabetes. Diabetologia. 2022; 65(11): 1758–1769.
    CrossRefPubMed
  11. Chiang JL, Kirkman MS, Laffel LMB, et al. Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014; 37(7): 2034–2054.
    CrossRefPubMed
  12. Bender C, Rodriguez-Calvo T, Amirian N, et al. The healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in type 1 diabetes. Sci Adv. 2020; 6(42).
    CrossRefPubMed
  13. Norose T, Ito Y, Ohike N. Two autopsy cases of mitochondrial disease (MELAS and MERRF) with special reference to the histological and immunohistochemical findings of the pancreatic islets. Pathol Int. 2020; 70(11): 915–917.
    CrossRefPubMed
  14. Corona G, Vena W, Pizzocaro A, et al. Testosterone therapy in diabetes and pre-diabetes. Andrology. 2023; 11(2): 204–214.
    CrossRefPubMed
  15. Liu J, Liu Z, Sun W, et al. Role of sex hormones in diabetic nephropathy. Front Endocrinol (Lausanne). 2023; 14: 1135530.
    CrossRefPubMed
  16. Van Cauwenberghe J, De Block C, Vanderschueren D, et al. Effects of treatment for diabetes mellitus on testosterone concentrations: A systematic review. Andrology. 2023; 11(2): 225–233.
    CrossRefPubMed
  17. La Vignera S, Condorelli R, Vicari E, et al. Diabetes mellitus and sperm parameters. J Androl. 2012; 33(2): 145–153.
    CrossRefPubMed
  18. Gupta C, Bubber P, Fahim M, et al. Adiponectin in onset and progression of T2DM with cardiac dysfunction in rats. Hum Exp Toxicol. 2020; 39(11): 1463–1474.
    CrossRefPubMed
  19. Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc. 2021; 1(4): e78.
    CrossRefPubMed
  20. Erendor F, Sahin EO, Sanlioglu AD, et al. Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation. Gene Ther. 2021; 28(3-4): 130–141.
    CrossRefPubMed
  21. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38(12): 1103–1111.
    CrossRefPubMed
  22. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004; 37(4): 277–285.
    CrossRefPubMed
  23. Ellidag HY, Eren E, Yılmaz N, et al. Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure. Redox Rep. 2014; 19(3): 118–123.
    CrossRefPubMed
  24. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000; 19(4): 311–315.
    CrossRefPubMed
  25. Mayoral LPC, Andrade GM, Mayoral EPC, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020; 151(1): 11–21.
    CrossRefPubMed
  26. Aras M, Tchang BG, Pape J. Obesity and Diabetes. Nurs Clin North Am. 2021; 56(4): 527–541.
    CrossRefPubMed
  27. Manna P, Jain SK. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. Metab Syndr Relat Disord. 2015; 13(10): 423–444.
    CrossRefPubMed
  28. Savini I, Catani MV, Evangelista D, et al. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci. 2013; 14(5): 10497–10538.
    CrossRefPubMed
  29. Masenga SK, Kabwe LS, Chakulya M, et al. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int J Mol Sci. 2023; 24(9).
    CrossRefPubMed
  30. Nono Nankam PA, Nguelefack TB, Goedecke JH, et al. Contribution of Adipose Tissue Oxidative Stress to Obesity-Associated Diabetes Risk and Ethnic Differences: Focus on Women of African Ancestry. Antioxidants (Basel). 2021; 10(4).
    CrossRefPubMed
  31. Gilbert M. Role of skeletal muscle lipids in the pathogenesis of insulin resistance of obesity and type 2 diabetes. J Diabetes Investig. 2021; 12(11): 1934–1941.
    CrossRefPubMed
  32. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 1999; 48(6): 1270–1274.
    CrossRefPubMed
  33. Itani SI, Zhou Q, Pories WJ, et al. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes. 2000; 49(8): 1353–1358.
    CrossRefPubMed
  34. Standaert ML, Bandyopadhyay G, Perez L, et al. Insulin activates protein kinases C-zeta and C-lambda by an autophosphorylation-dependent mechanism and stimulates their translocation to GLUT4 vesicles and other membrane fractions in rat adipocytes. J Biol Chem. 1999; 274(36): 25308–25316.
    CrossRefPubMed
  35. Dinić S, Arambašić Jovanović J, Uskoković A, et al. Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management. Front Endocrinol (Lausanne). 2022; 13: 1006376.
    CrossRefPubMed
  36. Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol. 2012; 167(1): 40–46.
    CrossRefPubMed
  37. Uskoković A, Mihailović M, Dinić S, et al. Administration of a β-glucan-enriched extract activates beneficial hepatic antioxidant and anti-inflammatory mechanisms in streptozotocin-induced diabetic rats. J Function Foods. 2013; 5(4): 1966–1974.
    CrossRef
  38. Rojas J, Bermudez V, Palmar J, et al. Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes Therapy. J Diabetes Res. 2018; 2018: 9601801.
    CrossRefPubMed
  39. Gurzov EN, Eizirik DL. Bcl-2 proteins in diabetes: mitochondrial pathways of β-cell death and dysfunction. Trends Cell Biol. 2011; 21(7): 424–431.
    CrossRefPubMed
  40. Kawano J, Arora R. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009; 4(1): 44–49.
    CrossRefPubMed
  41. Álvarez-Castro P, Pena L, Cordido F. Ghrelin in obesity, physiological and pharmacological considerations. Mini Rev Med Chem. 2013; 13(4): 541–552.
    CrossRefPubMed
  42. Ahima RS. Revisiting leptin's role in obesity and weight loss. J Clin Invest. 2008; 118(7): 2380–2383.
    CrossRefPubMed
  43. Ishikawa T, Fujioka H, Ishimura T, et al. Ghrelin expression in human testis and serum testosterone level. J Androl. 2007; 28(2): 320–324.
    CrossRefPubMed
  44. Page ST, Herbst KL, Amory JK, et al. Testosterone administration suppresses adiponectin levels in men. J Androl. 2005; 26(1): 85–92.
    PubMed
  45. Yuan F, Li YN, Liu YH, et al. Adiponectin inhibits the generation of reactive oxygen species induced by high glucose and promotes endothelial NO synthase formation in human mesangial cells. Mol Med Rep. 2012; 6(2): 449–453.
    CrossRefPubMed
  46. Aggerholm AS, Thulstrup AM, Toft G, et al. Is overweight a risk factor for reduced semen quality and altered serum sex hormone profile? Fertil Steril. 2008; 90(3): 619–626.
    CrossRefPubMed
  47. M Al-Ali B, Gutschi T, Pummer K, et al. Body mass index has no impact on sperm quality but on reproductive hormones levels. Andrologia. 2014; 46(2): 106–111.
    CrossRefPubMed
  48. Kanter M, Aktas C, Erboga M. Curcumin attenuates testicular damage, apoptotic germ cell death, and oxidative stress in streptozotocin-induced diabetic rats. Mol Nutr Food Res. 2013; 57(9): 1578–1585.
    CrossRefPubMed
  49. Mohasseb M, Ebied S, Yehia MAH, et al. Testicular oxidative damage and role of combined antioxidant supplementation in experimental diabetic rats. J Physiol Biochem. 2011; 67(2): 185–194.
    CrossRefPubMed
  50. Ghlissi Z, Hamden K, Saoudi M, et al. Effect of Nigella sativa seeds on reproductive system of male diabetic rats. Afr J Pharm Pharmacol. 2012; 6(20).
    CrossRef
  51. Hafez DA. Effect of extracts of ginger goots and cinnamon bark on fertility of male diabetic rats. J Am Sci. 2010; 6: 940–7.
  52. Ahangarpour A, Oroojan AA, Heidari H, et al. Effects of Hydro-alcoholic Extract from Arctium lappa L. (Burdock) Root on Gonadotropins, Testosterone, and Sperm Count and Viability in Male Mice with Nicotinamide/ Streptozotocin-Induced Type 2 Diabetes. Malays J Med Sci. 2015; 22(2): 25–32.
    PubMed
  53. Cameron DF, Rountree J, Schultz RE, et al. Sustained hyperglycemia results in testicular dysfunction and reduced fertility potential in BBWOR diabetic rats. Am J Physiol. 1990; 259(6 Pt 1): E881–E889.
    CrossRefPubMed
  54. Reddy KP, Narayana Rao M, Murthy JSR, et al. Lead aggravates the diabetic-induced reproductive toxicity in male Wistar rats. Toxicol Res (Camb). 2016; 5(5): 1465–1476.
    CrossRefPubMed
  55. Komaki K, Ohno Y, Aoki N. Gonadal hormones and gonadal function in type 2 diabetes model OLETF (Otsuka Long Evans Tokushima Fatty) rats. Endocr J. 2005; 52(3): 345–351.
    CrossRefPubMed
  56. De Young L, Yu D, Bateman RM, et al. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl. 2004; 25(5): 830–836.
    CrossRefPubMed
  57. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005; 90(5): 2636–2641.
    CrossRefPubMed
  58. Gobbo MG, Costa CF, Silva DG, et al. Effect of Melatonin Intake on Oxidative Stress Biomarkers in Male Reproductive Organs of Rats under Experimental Diabetes. Oxid Med Cell Longev. 2015; 2015: 614579.
    CrossRefPubMed
  59. Andlib N, Sajad M, Kumar R, et al. Abnormalities in sex hormones and sexual dysfunction in males with diabetes mellitus: A mechanistic insight. Acta Histochem. 2023; 125(1): 151974.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl